



**HAL**  
open science

## Management of SARS-CoV-2 pneumonia in intensive care unit: An observational retrospective study comparing two bundles

Alexandre Lopez, Ines Lakbar, Louis Delamarre, Aurélien Culver, Charlotte Arbelot, Gary Duclos, Emmanuelle Hammad, Bruno Pastene, François Antonini, Laurent Zieleskiewicz, et al.

### ► To cite this version:

Alexandre Lopez, Ines Lakbar, Louis Delamarre, Aurélien Culver, Charlotte Arbelot, et al.. Management of SARS-CoV-2 pneumonia in intensive care unit: An observational retrospective study comparing two bundles. *Journal of Critical Care*, 2021, 65, pp.200-204. 10.1016/j.jcrc.2021.06.014 . hal-03654564

**HAL Id: hal-03654564**

**<https://amu.hal.science/hal-03654564>**

Submitted on 2 Aug 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

TITLE PAGE

**Management of SARS-CoV-2 pneumonia in intensive care unit: an observational retrospective study comparing two bundles**

Alexandre Lopez, MD<sup>1</sup>; Ines Lakbar, MD<sup>2</sup>; Louis Delamarre, MD<sup>2</sup>; Aurélien Culver, MD<sup>1</sup>; Charlotte Arbelot, MD<sup>1</sup>; Gary Duclos, MD<sup>1</sup>; Emmanuelle Hammad, MD<sup>1</sup>; Bruno Pastene, MD<sup>1</sup>; François Antonini, MD<sup>1</sup>; Laurent Zieleskiewicz, MD, PhD<sup>1</sup>; Marc Leone, MD, PhD<sup>1</sup>

<sup>1</sup> Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Department of Anesthesiology and Intensive Care, Hôpital Nord, Marseille, 13015, France

<sup>2</sup> Department of Anesthesiology and Intensive Care Unit, Toulouse, France

**Author contact:**

Address: Alexandre Lopez, Department of Anesthesiology and Intensive Care Unit, Hôpital Nord, Chemin des Bourrely, 13015, Marseille, France.

Email: [7/5/2021 3:50:00 PM](mailto:alexandre.lopez@apmarseille.fr)

**Running title:** Two bundles of management of severe SARS-CoV-2 pneumonia

**Word count:** 2086

**Abstract count:** 200

**References count:** 21

**Tables:** 2

**Figures:** 2

This article has an online data supplement.

## HIGHLIGHTS

- Changes in therapeutic strategies might have no effect in-hospital mortality rate in SARS-CoV-2 pneumonia but reduced the length of stay in intensive care unit and in-hospital.
- The management of respiratory support may have influenced outcome's patient.
- Other factors as knowledge on COVID-19 pathophysiology and improvement in hospital organization may have impacted in-hospital mortality.

## ABSTRACT

### Purpose

To compare the effects of two therapeutic bundles of management in SARS-CoV2 ICU patients.

### Materials

### and

### Methods

Our retrospective, observational study was performed in a university ICU from March to June 2020 (first wave) and from September 2020 to January 2021 (second wave). In first wave, patients received bundle 1 including early invasive ventilation, hydroxychloroquine, cefotaxime and azithromycin. In second wave, bundle 2 included non-invasive oxygenation support and dexamethasone. The main outcome was in-hospital mortality. Secondary outcomes included ICU and hospital length of stay, ICU supportive therapies, viral clearance and antimicrobial resistance emergence.

### Results

129 patients with SARS-CoV-2 pneumonia were admitted to our ICU. Thirty-five were treated according to bundle 1 and 76 to bundle 2. In-hospital mortality was similar in the two groups (23%,  $p=1$ ). The hospital ( $p=0.003$ ) and ICU ( $p=0.01$ ) length of stay and ventilator-free days at 28 days ( $p=0.03$ ) were significantly reduced in bundle 2. Increasing age, vasopressor use and  $\text{PaO}_2/\text{FiO}_2$  ratio  $< 125$  were associated with in-hospital mortality.

### Conclusion

Within the limitations of our study, changes in therapeutic bundles for SARS-Cov-2 ICU patients might have no effect on in-hospital mortality but were associated with less exposure to mechanical ventilation and reduced hospital length of stay.

**Keywords:** COVID-19, Intensive care unit, treatment, hydroxychloroquine, dexamethasone, bundle

## **INTRODUCTION**

Since the World Health Organization announced the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak (1), many antivirals and immunomodulatory drugs have been proposed (2) to improve outcomes of patients admitted to the hospital. In addition, strategies regarding oxygenation support have been discussed at length.

During the first wave lasting from March to May 2020, hydroxychloroquine (HCQ) and azithromycin (AZT) were extensively used to reduce the viral load of SARS-CoV-2 in patients with mild to severe disease (1)(2). However, several studies suggested that HCQ use failed to improve the prognosis in SARS-CoV-2 intensive care unit (ICU) patients (3). The RECOVERY study, a large trial that randomized 4717 patients, found no difference in 28-day mortality between the patients treated with and those who did not receive this drug (4). In addition, several lines of evidence showed a low rate of bacterial infections in the ICU admission of patients with SARS-CoV-2, suggesting that early antibiotic treatment was not systematically required in those patients. From a ventilator-related standpoint, early invasive mechanical ventilation was suggested as safe with regard to the risks associated with the use of non-invasive respiratory supports (5).

In contrast, glucocorticoids (6) (7) emerged as an interesting treatment in SARS-CoV-2 pneumonia. The administration of dexamethasone (DXM) has been associated with reduced in-hospital mortality (8). In addition, practices have changed for correcting hypoxemia with a larger use of non-invasive respiratory supports.

Most of these treatments have been assessed as single interventions in many publications (9), but to our knowledge, studies comparing the effects of two different bundles of management are scarce. The first aim of our study was to compare the effects of two bundles of treatment in the management of SARS-CoV-2 pneumonia in ICU patients on in-hospital mortality rate. The secondary aim of this study was to determine if one of the two bundles was associated with a shorter duration of ICU and hospital stays.

## **METHODS**

### *Design*

This single-center, retrospective, observational study was performed in the polyvalent ICU of the North University Hospital of Marseille. The first and second waves lasted from March 2020 to June 2020 and from September 2020 to January 2021, respectively. The study was compliant with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations (10).

### *Ethical considerations*

The study was approved by the Committee for Research Ethics of the French Society of Anesthesia & Intensive Care Medicine (CERAR no. IRB 00010254 – 2020 - 257). Patients were informed regarding the use of their data. The different treatment strategies being considered as standard care, informed consent was waived, according to French law (11).

### *Population*

Confirmed Corona Virus disease 2019 (COVID-19) patients with acute respiratory failure were included if they completed the following criteria: i) adult patients with a SARS-CoV-2 infection confirmed by real-time reverse transcriptase polymerase chain reaction (RT-PCR) of nasopharyngeal samples upon ICU admission (12) and ii) respiratory support therapy (conventional oxygen therapy, high flow nasal oxygenation, non-invasive or invasive mechanical ventilation) for hypoxemia defined as an oxygen saturation below 90%. The exclusion criteria were as follows: patients with a known allergy or contraindication to HCQ, AZT, or DXM and those treated with other drugs (lopinavir/ritonavir). We identified two different groups: patients undergoing bundle 1 treatment during the first wave (HCQ plus AZT plus cefotaxime) and those undergoing bundle 2 treatment during the second wave (DXM alone).

### *Study protocol*

At ICU admission, each patient's demographic, clinical, and biological data were collected, and the Simplified Acute Physiology Score II (SAPS II) and the Sepsis-related Organ Failure Assessment (SOFA) score were calculated. COVID-19 features, such as the duration of symptoms and the onset of disease, were reported. The use of vasopressors, the use of antibiotics, and the duration of mechanical ventilation were also recorded. The viral load was determined from nasopharyngeal swab samples collected at ICU admission and every 72 hours by polymerase chain reaction (PCR). The follow-up of each patient lasted 28 days.

The first bundle consisted of an 800 mg loading dose of HCQ on the first day of treatment and a maintenance dose of 400 mg for nine days. The additional treatment consisted of a 500 mg loading dose of AZT followed by a 250 mg maintenance dose associated with cefotaxime (6 g a day administered by continuous infusion) for five days. Then, antibiotics were provided if a bacterial infection was documented. High-dose steroids (methylprednisolone 2 mg/kg) were administered in patients developing prolonged acute respiratory distress syndrome with

elevated serum and alveolar concentrations of procollagen type III (13). In those patients, tracheal intubation and mechanical ventilation were performed early in case of desaturation (pulse oximetry below 90% under maximal oxygen support). The second bundle consisted of the use of DXM at a dose of 6 mg per day for 10 days. Neither antivirals nor antibiotics were used with the exception of suspected or documented bacteria pneumonia, based on evaluative image of the chest X-ray, increase in inflammatory biomarkers (CRP and procalcitonin), hemodynamic instability requiring the introduction of norepinephrine, and identification of bacteria on directed samples. The second wave patients received oxygen by the use of non-invasive respiratory supports, recourse to intubation being required only in case of desaturation after non-invasive respiratory support failure. Anticoagulation protocols did not differ between the two groups, according to international guidelines (14) (e-Table 1).

### *Outcomes*

The first endpoint was in-hospital mortality rate in the two groups. The secondary endpoints were ICU mortality rates, length of ICU and hospital stays, duration of mechanical ventilation (ventilator free-days), vasopressor use, antibiotic use, the number of patients with negative PCR at Day 15, and ICU-acquired infection rates.

### *Statistical analysis*

The necessary number of patients to be included was not calculated *a priori*; all the patients admitted to our ICU during the study period were eligible. Categorical variables were reported as absolute frequencies and proportions. Continuous variables were reported as median (interquartile range) or mean (standard deviation) when needed. Normal distribution was evaluated using the Kolmogorov-Smirnov test and skewness and kurtosis coefficients. The Mann-Whitney U test was used to compare continuous variables between groups in the case of non-normally distributed data, and the Student t test was used in the case of normal distribution. Chi-squared test ( $X^2$ ) was used to compare qualitative variables between groups, except for variables in which the expected number of variable occurrences was  $< 5$ , where Exact Fisher test was used. Bivariate logistic regression was performed on qualitative variables and quantitative variables of interest after binarization around their median or a validated threshold. Age was binarized around its median (66 years-old), ratio of arterial oxygen partial to fractional inspired oxygen ( $PaO_2/FiO_2$ ) around its median (125 mmHg) and admission cycle threshold (Ct) of PCR assay around its median (29).

Statistical significance was defined as  $p < .05$ . Analyses were performed using R software 4.0.4 for Windows (R Core Team, R Foundation for Statistical Computing, Vienne, Austria, 2021).

## RESULTS

From March 2020 to January 2021, 129 patients with SARS-CoV-2 pneumonia were admitted to our ICU. Among them, 35 patients were treated according to bundle 1 and 76 patients according to bundle 2 (Figure 1). The demographic characteristics, clinical features, and severity scores did not differ between both groups, with the exception of age (62 [52-72] years in bundle 1 vs. 67 [60-73] years in bundle 2,  $p=0.03$ ) and viral load at admission (31 [28-33] Ct in bundle 1 vs. 24 [24-32] Ct in bundle 2,  $p=0.02$ ).

### *Primary outcome*

Eight patients (23%) from the bundle 1 group and 16 (21%) patients from the bundle 2 group did not survive to hospital discharge ( $p=0.97$ ) (Figure 2).

### *Secondary outcomes*

The hospital length of stay (25 [13-44] vs. 13 [9-24] days,  $p=0.003$ ) and the ICU length of stay (16 [5-32] vs. 7 [3-15] days,  $p=0.01$ ) were shorter in the bundle 2 group (see Table 1). The use of vasopressors and mechanical ventilation was similarly distributed in both groups ( $p=0.31$  and  $p=0.14$ , respectively, Table 1). At day 28, the number of ventilator-free days was reduced in the bundle 1 group, as compared with the bundle 2 group ( $p=0.03$ ). High flow nasal cannula oxygenation was mostly used in the bundle 2 group ( $p=0.03$ ). No statistical difference was found for ICU-acquired infections (12 (34%) vs. 26 (34%),  $p=1$ ) (Table 1). There was no difference in antibiotics use after excluding those given for prophylaxis ( $p=0.56$ ) but and high-dose steroid uses ( $p=1$ ) between the two groups (Table 1). During the ICU stay, no significant differences were observed in the emergence of multidrug resistant bacteria ( $p=0.39$ ) (Table 1). The ICU mortality rate did not differ between the two groups ( $p=0.9$ ) (Figure 2).

The type of management bundle was not associated with in-hospital mortality (OR: 1.1, 95% CI: 0.4 – 3.2;  $p = 0.8$  for Bundle 1 vs. Bundle 2). Age > 66 years (OR: 19.4, 95% CI: 4.4 - 123.4;  $p<0.001$ ), vasopressors use (OR: 7.6, 95% CI: 2.2 – 26.3;  $p<0.001$ ), PaO<sub>2</sub>/FiO<sub>2</sub> ratio < 125 (OR: 5.8, 95% CI: 1.9 – 17.7,  $p<0.001$ ) were associated with in-hospital mortality, as



well as high viral load at the ICU admission, mechanical ventilation, SAPS II > 33 and antibiotics use (Table 2).

## **DISCUSSION**

Our study compared two bundles to manage severe SAR-CoV-2 patients admitted to a single ICU. Although no difference was found in-hospital mortality rate, the patients in the bundle 2 group were less exposed to mechanical ventilation, ICU, and hospital length of stay than those in the bundle 1 group. During a pandemic, due to the high need for ICU beds (15)(16), the reduction in the duration of length of stay in ICU should be regarded as a significant finding. This result may favor higher rotation of patients in both ICU and hospital beds. Regarding the burden of care, the difference between the two groups did not seem irrelevant because more ICU beds and staff members were available during the second wave. Therefore, the workload was equal for both medical and nursing staff.

As we compared bundles retrospectively, no conclusion can be drawn on the effects of each single intervention. However, we note that the systematic use of prophylactic antibiotics was not associated with a reduction in ICU-acquired infection. We previously showed that therapeutic serum concentrations of HCQ were not associated with improved viral clearance and improved outcomes (2). Thus, our present findings are in line with our previous finding (2), re-enforcing the lack of efficacy of HCQ in severe cases requiring ICU admission. Considering everything, we suggest that the different strategies regarding oxygenation may have played a major role in the differences in ICU stays between the two groups, although, once again, it is difficult to identify the role of a single intervention.

Our study has limitations that need to be acknowledged. It is a single-center study involving a small number of patients, which cannot be generalized. As such, the results from bivariate analysis should be interpreted with caution regarding the small number of events (in-hospital deaths) in some variables. Another study has suggested a decrease in mortality during the second wave (17). As we compared several interventions including management of respiratory support, it is unclear which of them may have influenced our final findings on outcome. Finally, the bundles were not randomized, and a time effect cannot be ruled out.

During the first wave, physicians were reluctant to use non-invasive oxygenation support for fear of spreading an airborne virus (18), whereas in the second wave non-invasive support use was encouraged (19) (20). Our data on respiratory management lacked sufficient granularity to allow us to understand whether this approach led to delayed intubations (higher oxygen

demand or lower PaO<sub>2</sub>/FiO<sub>2</sub> before intubation) in the second wave. This might be a limitation of our study. Another limitation of our study can be related to the lack of data regarding the specific elements of COVID-19 disease severity (such as imaging data (21)) as disease severity was only assessed by general severity scores in our cohort. Other factors such as knowledge on COVID-19 physiopathology and improvement in hospital organization may have impacted in-hospital mortality and were not measured in this study.

In conclusion, within the limitations of this study, our results suggest that changes in treatment strategies in SARS-CoV-2 ICU patients might not affect in-hospital mortality rate but were associated with less exposure to mechanical ventilation and reduced use of resources. These findings need to be confirmed in large and multicentric randomized controlled trials.

### **ACKNOWLEDGEMENT**

The authors are indebted to the nurses and the ICU staff managing SARS-CoV-2 patients' bedsides.

### **FUNDING**

None

### **CONFLICTS OF INTEREST**

ML served as lecturer for MSD, Aspen and consultant for Gilead, Amomed. All other authors report no conflicts of interest.

## REFERENCES

1. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020 Mar 20;105949.
2. Lopez A, Duclos G, Pastene B, Bezulier K, Guilhaumou R, Solas C, et al. Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results. *Int J Antimicrob Agents*. 2020 Nov;56(5):106136.
3. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ*. 2020 May 14;369:m1849.
4. RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*. 2020 Nov 19;383(21):2030–40.
5. Esteban A, Anzueto A, Frutos F, Alía I, Brochard L, Stewart TE, et al. Characteristics and Outcomes in Adult Patients Receiving Mechanical VentilationA 28-Day International Study. *JAMA*. 2002 Jan 16;287(3):345–55.
6. Meduri GU, Carratu P, Freire AX. Evidence of biological efficacy for prolonged glucocorticoid treatment in patients with unresolving ARDS. *Eur Respir J Suppl*. 2003 Aug;42:57s–64s.
7. Zhao Q, Shi J-X, Hu R, Li Q, Zhang C-Y, Li J-S. Effect of glucocorticoids on mortality in patients with acute respiratory distress syndrome: A meta-analysis. *Exp Ther Med*. 2019 Dec;18(6):4913–20.
8. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med*. 2020 Jul 17;
9. Gautret P, Million M, Jarrot P-A, Camoin-Jau L, Colson P, Fenollar F, et al. Natural history of COVID-19 and therapeutic options. *Expert Rev Clin Immunol*. 2020 Dec 24;1–24.
10. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol*. 2008 Apr;61(4):344–9.
11. Toulouse E, Lafont B, Granier S, Mcgurk G, Bazin J-E. French legal approach to patient consent in clinical research. *Anaesth Crit Care Pain Med*. 2020 Dec;39(6):883–5.
12. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA*. 2020 May 12;323(18):1843–4.
13. Forel J-M, Guervilly C, Hraiech S, Voillet F, Thomas G, Somma C, et al. Type III procollagen is a reliable marker of ARDS-associated lung fibroproliferation. *Intensive Care Med*. 2015 Jan;41(1):1–11.
14. Susen S, Tacquard CA, Godon A, Mansour A, Nguyen P, Godier A, et al. TRAITEMENT ANTICOAGULANT POUR LA PREVENTION DU RISQUE THROMBOTIQUE CHEZ UN PATIENT HOSPITALISE AVEC COVID-19 ET SURVEILLANCE DE L'HEMOSTASE PROPOSITIONS DU GIHP ET DU GFHT. :5.
15. Phua J, Weng L, Ling L, Egi M, Lim C-M, Divatia JV, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. *Lancet Respir Med*. 2020 May;8(5):506–17.
16. Ma X, Vervoort D. Critical care capacity during the COVID-19 pandemic: Global availability of intensive care beds. *J Crit Care*. 2020 Aug;58:96–7.
17. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group,

Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA*. 2020 Oct 6;324(13):1330–41.

18. Zhang R, Li Y, Zhang AL, Wang Y, Molina MJ. Identifying airborne transmission as the dominant route for the spread of COVID-19. *PNAS*. 2020 Jun 30;117(26):14857–63.

19. Winck JC, Ambrosino N. COVID-19 pandemic and non invasive respiratory management: Every Goliath needs a David. An evidence based evaluation of problems. *Pulmonology*. 2020 Aug;26(4):213–20.

20. Cinesi Gómez C, Peñuelas Rodríguez Ó, Luján Torné M, Egea Santaolalla C, Masa Jiménez JF, García Fernández J, et al. [Clinical consensus recommendations regarding non-invasive respiratory support in the adult patient with acute respiratory failure secondary to SARS-CoV-2 infection]. *Med Intensiva*. 2020 Oct;44(7):429–38.

21. Zieleskiewicz L, Markarian T, Lopez A, Taguet C, Mohammedi N, Boucekine M, et al. Comparative study of lung ultrasound and chest computed tomography scan in the assessment of severity of confirmed COVID-19 pneumonia. *Intensive Care Med*. 2020 Jul 29;1–7.

**Table 1: Demographic and clinical findings**

<b>Variables</b>	<b>Bundle 1 (n = 35)</b>	<b>Bundle 2 (n = 76)</b>	<b>p</b>
<b>Demographics and severity</b>			
Age, median [IQR], (years)	62 [52-72]	67 [60-73]	0.03
<b>Sex</b>			
Men, n (%)	27 (77)	55 (72)	0.76
<b>Comorbidities, n (%)</b>			
BMI > 25 kg/m <sup>2</sup>	29 (83)	62 (82)	1
Pregnancy	3 (9)	1 (1)	0.09
Coronary disease	9 (26)	15 (20)	0.64
Hypertension	24 (69)	40 (53)	0.16
COPD	4 (11)	11 (15)	0.77
Cancer	4 (11)	13 (17)	0.63
Immunosuppression <sup>a</sup>	2 (6)	10 (13)	0.33
Chronic kidney disease	1 (3)	5 (7)	0.66
Liver disease	1 (3)	1 (1)	0.53
Active smoker	8 (23)	11 (15)	0.41
Diabetes	15 (43)	22 (29)	0.21
SAPS II at admission, median [IQR] <sup>b</sup>	31 [23-38)	34 [30-42]	0.12
SOFA at admission, median [IQR]	3 [2-5]	3 [2-4]	0.37
PaO <sub>2</sub> /FiO <sub>2</sub> ratio at admission, median [IQR] (mmHg)	145 [108-190]	123 [93-165]	0.15
Duration of symptoms before hospital admission, mean ± SD (days)	5 ± 3	5 ± 6	0.86
Duration of symptoms before ICU admission, mean ± SD (days)	6 ± 4	7 ± 6	0.37
Duration of symptoms before mechanical ventilation, median [IQR] (days)	1 (1-3)	1 (0-4)	0.72
Viral load at admission, median [IQR] (Ct of PCR assay)	31 [28-33]	24 [24-32]	0.02
<b>Interventions and clinical findings</b>			

Mechanical ventilation, n (%)	23 (66)	37 (48)	0.14
High flow nasal oxygen, n (%)	25 (71)	67 (88)	0.06
Ventilator-free days (28 days), median [IQR] (days)	13 [0-28]	28 [1-28]	0.03
Vasopressors use, n (%)	20 (57)	34 (44)	0.31
Thrombosis, n (%)	9 (26)	10 (13)	0.17
Antibiotic use*, n (%)	18 (51)	33 (43)	0.56
Antibiotic-free days (including prophylaxis), median [IQR] (days)	18 [16-23]	28 [21-28]	< 0.001
Antibiotic-free days (excluding prophylaxis), median [IQR] (days)	23 [21-28]	28 [21-28]	0.3
High dose of steroids Methylprednisolone 2 mg/kg, n (%)	2 (6)	5 (7)	1
ICU-acquired infections, n (%)	12 (34)	26 (34)	1
	Pneumonia	9	15
	Bacteremia	3	2
	Intra-abdominal	0	3
	Other site	0	5
<b>Bacteria</b>			
	Gram-negative bacteria	5	13
	Gram-positive cocci	4	7
	Others	0	5
Multidrug resistant bacteria during ICU stay, n (%)	7 (20)	9 (12)	0.39
Renal replacement therapy, n (%)	3 (9)	2 (3)	0.32
ECMO recourse, n (%)	3 (9)	2 (3)	0.32
<b>Outcomes</b>			
Length of hospital stay, median [IQR] (days)	25 [13-44]	13 [9-24]	0.003
Length of ICU stay, median [IQR] (days)	16 [5-32]	7 [3-15]	0.01
Negative PCR Day 15	25 (71)	55 (72)	1
<i>Abbreviations:</i> BMI, Body mass index; SAPS II, Simplified acute physiology score II;			

SOFA, Sepsis-related organ failure assessment; PaO<sub>2</sub>/FiO<sub>2</sub>, ratio of arterial oxygen partial to fractional inspired oxygen; PCR, Polymerase Chain reaction; Ct, Cycle threshold; ECMO, Extracorporeal membrane oxygenation; ICU, Intensive care unit; IQR, Interquartile range; SD, Standard derivation.

<sup>a</sup> Immunodepression: HIV patients, transplant patients, patients undergoing immunosuppressive treatment.

<sup>b</sup> The SAPS II ranges from 0 to 163, with higher scores indicating a higher risk of mortality. A patient with a score of 30 has an estimated mortality risk of 10%.

\* Except with antimicrobials administered systematically according to bundle 1

**Table 2: Bivariate analyses of variables in association with in-hospital mortality.**



	Univariate analysis			
	In-hospital survival n (%) n = 88	In-hospital mortality n (%) n = 23	OR (95% CI)	p
Age > 66 years old	29 (33)	21 (91)	19.4 (4.4 – 123.4)	<0.001
PaO <sub>2</sub> /FiO <sub>2</sub> ratio <125 mmHg	32 (36)	18 (78)	5.8 (1.9 – 17.7)	<0.001
Viral load at admission > 29 (Ct of PCR assay)	36 (41)	16(70)	3 (1.1 – 9.3)	0.03
SAPS II at ICU admission > 33	33 (38)	18 (78)	5.5 (1.8 - 16.8)	<0.01
SOFA score at ICU admission > 3	31 (35)	12 (52)	1.9 (0.7 - 4.8)	0.23
Bundle 1	27 (31)	8 (35)	1.1 (0.4 - 3.2)	0.8
Coronary disease	15 (17)	8 (35)	2.4 (0.8 – 7.1)	0.09
COPD	9 (10)	5 (22)	2.3 (0.7 – 8.3)	0.17
Cancer	11 (13)	6 (22)	2.3 (0.7 – 7.2)	0.19
Mechanical ventilation	38 (43)	18 (78)	4.3 (1.4 – 13.2)	0.01
Vasopressors use	32 (36)	19 (83)	7.6 (2.2 – 26.3)	<0.001
ICU-acquired infections	24 (27)	11 (48)	2.3 (0.9 – 5.9)	0.13
Antibiotic use	32 (36)	15 (65)	3 (1.1 – 8)	0.03
Women	24 (27)	4 (17)	0.5 (0.2-1.7)	0.4
Obese (BMI > 25 kg/m <sup>2</sup> )	32 (36)	8 (35)	0.9 (0.3 - 2.4)	0.8

*Abbreviations:* BMI, body mass index; COPD, chronic obstructive lung disease; Ct, Cycle

threshold; ICU, intensive care unit; PaO<sub>2</sub>/FiO<sub>2</sub>, ratio of arterial oxygen partial to fractional inspired oxygen; PCR, polymerase chain reaction; SAPS, severity acute physiology score; SOFA, sequential organ failure assessment; OR, odds ratio; CI, confidence interval.

**Figure 1: Flow chart**

**Figure 2: ICU and in-hospital mortalities between the two groups**

Bundle 1 and Bundle 2 are represented in dark blue and dark orange respectively.

ICU mortality:  $p=0.91$  and in-hospital mortality:  $p=0.97$

**129 patients assessed for eligibility**

**18 excluded patients**  
10 other antiviral treatment  
4 contraindications  
4 missing data

**111 patients assessed for eligibility**

**35 patients**  
**Bundle 1**

**76 patients**  
**Bundle 2**

Mortality rate

30%

25%

20%

15%

10%

5%

0%



ICU



In-Hospital

